Table 1 Demographic data of patients
From: Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?
Sex | ||
Men | 114 | 54.50 % |
Woman | 99 | 45.50 % |
Age (years) | ||
Median (range) | 61.65 | 29–88 |
<70 | 152 | 71.40 % |
≥70 | 61 | 28.60 % |
Performance status | ||
0 | 193 | 90.60 % |
1 | 17 | 8.00 % |
2 | 3 | 1.40 % |
Median OPD follow-up (months) | 54.03 | |
5 year survival rate | 77.90 % | |
5 year cancer specific survival | 82.20 % | |
3 year disease free survival | 76.70 % | |
Recurrence rate | 26.30 % | |
Pathological staging | ||
pT classification | ||
pT1–3 | 193 | 90.60 % |
pT4 | 20 | 9.40 % |
pN classificaton | ||
pN1 | 128 | 60.10 % |
pN2 | 85 | 39.90 % |
Tumor localization | ||
Right | 85 | 40.40 % |
Left | 128 | 59.60 % |
Obstruction/Perforation | 35 | 16.40 % |
Histopathology grade | ||
Well, and moderate differentiated | 188 | 88.30 % |
Poor differentiated | 22 | 10.30 % |
Missing | 3 | 1.40 % |
Pre-operative CEA level | ||
CEA >5 | 70 | 32.9 % |
CEA ≤5 | 131 | 61.5 % |
Missing | 12 | 5.6 % |
Time to chemotherapy (weeks) | ||
≥8 | 10 | 4.70 % |
<8 | 203 | 95.30 % |
Lymph nodes harvested | ||
Lymph nodes <12 | 19 | 8.90 % |
Lymph nodes ≥12 | 194 | 91.10 % |